Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Berberol
- Development stage
- Unknown
- Lead developer
- Pharmextracta
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Berberol is a patented fixed-dose combination of Berberis aristata (standardized for berberine) and Silybum marianum (standardized for silymarin) developed by PharmExtracta. It is used as a nutraceutical supplement to improve glycemic control, insulin sensitivity, and lipid profiles in patients with type 1 or type 2 diabetes, dyslipidemia, metabolic syndrome, or those who are intolerant to statins. Berberine, the active alkaloid from Berberis aristata, acts primarily by activating the AMP-activated protein kinase (AMPK) pathway, which enhances glucose uptake and lipid metabolism, and by upregulating LDL receptor expression. Silymarin, derived from Silybum marianum, acts as a bioenhancer by inhibiting P-glycoprotein (P-gp) efflux, thereby significantly increasing the intestinal absorption and bioavailability of berberine, while also providing antioxidant and hepatoprotective benefits.
- Brand names
- BerberolBerberol KBerberol P
- Other names
- Berberis aristata and Silybum marianumBerberis aristata/Silybum marianumberberine + silymarinberberine/silymarin
02
Targets
ABCB1 (P-glycoprotein)SIRT1 (NAD-dependent protein deacetylase sirtuin-1)
Beyond the preview
Go deeper on Berberol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Berberol.